Endoluten is often discussed in connection with sleep, hormonal balance, and healthy aging. A human clinical report offers a more specific picture: it examined patients with four different sets of health concerns and described changes in symptoms and selected blood measurements.
For an introduction to the product and its proposed role in pineal gland support, read our Endoluten overview. Here, we take a closer look at the human research and what the reported findings could mean for you.
Looking at each group separately helps answer the questions that matter to readers: who participated, what changed, and what might those changes mean?
One study, four clinical groups
The 2011 St. Petersburg report included 163 participants. Within each diagnostic group, patients received conventional care alone or conventional care with Endoluten added.[1,2]
Patient group | Age range | Conventional care | Care plus Endoluten | Total |
|---|---|---|---|---|
| Women with menopausal symptoms | 42–63 | 16 | 27 | 43 |
| Patients after radiation and chemotherapy | 48–76 | 29 | 40 | 69 |
| Men with asthenia | 18–42 | 9 | 14 | 23 |
| Women with “dyshormonal myocardial dystrophy” | 40–59 | 10 | 18 | 28 |
| Total | 64 | 99 | 163 |
These were four subgroups within one clinical investigation, not four independent trials. The findings concern Endoluten used alongside medical care.
1. Women with menopausal symptoms
Who participated?
This subgroup involved 43 women experiencing menopausal symptoms.[1]
What changed?
The symptom table reports the following proportions after treatment:[1]
| Symptom | Conventional care | Care plus Endoluten |
|---|---|---|
| Sleep disturbances | 47.6% | 22.1% |
| Hot flashes | 59.4% | 26.2% |
| Rapid fatigability | 53.9% | 32.6% |
| Irritability | 62.5% | 36.1% |
The authors also described continued symptom relief one to two months after treatment.[1]
What do the findings suggest?
The reported improvements span nighttime symptoms and daytime well-being, including fewer sleep disturbances, hot flashes, episodes of rapid fatigue, and complaints of irritability in the Endoluten group. These symptoms can overlap: night sweats can interrupt sleep, while poor sleep can contribute to daytime fatigue during the menopausal transition.[8]
However, these percentages are reported symptom frequencies, not cure rates. Their relationship to the stated group sizes is unclear, and the table gives a shared pretreatment column. They should be read as exploratory observations.
2. Patients recovering after radiation and chemotherapy
Who participated?
This subgroup included 69 men and women after cancer treatment.[2]
What changed?
Researchers reported improved appetite, sleep, muscle tone, and apathy, alongside increases in selected white-cell measurements. For example, mean lymphocyte counts were 1.42 after conventional care and 1.78 after care including Endoluten, in units of ×10⁹/L.[2]
What do the findings suggest?
These observations concern recovery and supportive care. Feeling more able to eat, sleep, and resume activities would be meaningful to a recovering patient. The increases in white-cell and lymphocyte counts are potentially meaningful because cancer treatment can suppress the bone marrow’s production of blood cells. Rising counts after treatment can be consistent with recovery of blood-cell production and immune-cell populations. The findings therefore suggest a possible contribution to recovery when Endoluten was added to conventional care, although the study did not directly demonstrate bone marrow regeneration or establish that Endoluten was responsible for the changes.
The findings do not demonstrate cancer treatment, prevention of recurrence, or improved survival. Decisions about supplements during or after cancer care should be made with the treating oncology team.
3. Men with asthenia
Who participated?
The report included 23 men with asthenia, a term for weakness or fatigue.[2]
What changed?
The investigators described relief of symptoms and improved general condition, with improvements persisting for approximately one to three months after treatment.[2]
What do the findings suggest?
For this group, the relevant question was everyday functioning. The observations suggest a possible role worth investigating in people with similar symptoms, rather than evidence of an energy boost for healthy adults.
Asthenia is a description of symptoms, not an explanation of their cause. These findings should not be extended to every form of fatigue or treated as evidence for conditions such as ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome). The report also does not establish permanent recovery.
4. Women with hormone-associated cardiac symptoms
Who participated?
This subgroup included 28 women diagnosed with “dyshormonal myocardial dystrophy,” the report’s term attributing heart-muscle disturbances to hormonal changes.[2]
What changed?
The authors described fewer episodes of pain in the heart region, improved working capacity, and favorable ECG changes. They also reported the following mean hormone measurements:[2]
| Measurement | Pretreatment* | After conventional care | After care plus Endoluten |
|---|---|---|---|
| FSH, mU/mL | 89.3 | 71.6 | 46.8 |
| LH, mU/mL | 28.1 | 25.7 | 16.4 |
| Estradiol, pmol/L | 65.4 | 79.1 | 101.3 |
The source gives one pretreatment column rather than separate baselines for each arm. Accompanying uncertainty terms are omitted here for readability.
What do these hormones tell us?
FSH, or follicle-stimulating hormone, is made by the pituitary gland at the base of the brain. It helps ovarian follicles develop and supports estrogen production.[4]
LH, or luteinizing hormone, also comes from the pituitary gland. Its midcycle surge triggers ovulation.[5]
Estradiol, or E2, is the main estrogen in nonpregnant women of reproductive age. It supports reproductive function as well as bone and brain health.[6]
In the study’s hormone-associated cardiac subgroup, FSH and LH decreased while estradiol increased, with larger changes reported among women receiving Endoluten alongside conventional care. This pattern is compatible with increased estrogen feedback to the pituitary, reducing its signals to the ovaries.
These findings suggest a possible influence on hormonal regulation, rather than proof of restored ovarian function or reversed menopause. Higher FSH and LH can be normal after menopause, so lower readings alone should not be interpreted as better health.
How does this relate to heart health?
Endoluten treatment was associated with a shift in reproductive hormone measurements that accompanied reported symptom improvements. Hormonal changes around menopause occur alongside changes in blood-vessel health, cholesterol, and body-fat distribution. The American Heart Association identifies the menopausal transition as an important period for cardiovascular prevention.[9]
What can readers take from these findings?
Across the four patient groups, adding Endoluten to conventional care was associated with several positive findings. Women with menopausal symptoms reported fewer sleep disturbances, hot flashes, episodes of fatigue, and complaints of irritability. Patients recovering after cancer treatment experienced improvements in appetite, sleep, and general well-being, alongside increases in selected white-cell counts consistent with immune-cell recovery. Men with asthenia showed relief of weakness and fatigue, while women with hormone-associated cardiac complaints had lower FSH and LH, higher estradiol, and reported improvements in symptoms and ECG findings. Together, these preliminary observations suggest potential benefits for symptoms and recovery, without establishing that Endoluten alone caused the changes.
Each group addresses a different question: menopausal symptom relief, recovery after treatment, fatigue-related functioning, or hormonal changes accompanying cardiac complaints. Findings in one group cannot automatically answer questions about another.
The report describes favorable tolerability, but does not establish long-term safety.[2] It is available in commercial report materials; an independently peer-reviewed publication of this specific investigation was not verified. These limitations temper confidence without erasing the observations.
For readers examining the product, GARMONIA Endoluten A-8 at Vita Stream is listed as containing 10 mg of natural pineal peptide complex per capsule.[3]
The human report offers specific findings to discuss with a qualified healthcare professional. It does not establish that Endoluten extends lifespan, replaces medical treatment, or produces the same benefits in healthy people.
Use discount code APIC10 at checkout to receive 10% off your purchase at Vita Stream.
Sources
- Khavinson, V. Report on the results of clinical study of peptide bioregulator Endoluten.
Commercially hosted investigator-attributed report. - Reports on the results of clinical studies of peptide bioregulators of the CYTOMAX and CYTOGEN class. Endoluten section. Sources 1 and 2 describe the same investigation, not independent replications.
- Vita Stream. Endoluten A-8 product information, linked above.
- MedlinePlus. Follicle-stimulating hormone (FSH) blood test.
- MedlinePlus. Luteinizing hormone (LH) levels test.
- MedlinePlus. Estrogen levels test.
- Hall JE. Endocrinology of the Menopause. Endocrinology and Metabolism Clinics of North America. 2015.
- National Institutes of Health. Menopause.
- American Heart Association. Menopause transition and cardiovascular disease risk: key points.
